Evidence map›Paper›PMID 27089170›Full record

Trial reportFuture oncology (London, England)2016

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.

Grzegorz S Nowakowski, Annalisa Chiappella, Thomas E Witzig, Michele Spina, Randy D Gascoyne, Lei Zhang, Jocelyne Flament, Jacqueline Repici, Umberto Vitolo

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02285062 (Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02285062 phase3completednot on this map

Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma

TypeinterventionalSponsorCelgeneRan2015 to 2022Enrolled570ConditionsLymphoma, Large B-Cell, DiffuseArmslenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Cost-effectiveness of HLX01 (HanlikangFrontiers in pharmacology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic, Rochester, MN 55902, USA.
Annalisa ChiappellaDivision of Hematology, Città della Salute e della Scienza Hospital & University, Torino, Italy.
Thomas E WitzigDivision of Hematology, Mayo Clinic, Rochester, MN 55902, USA.
Michele SpinaDivision of Medical Oncology, National Cancer Institute, Aviano, Italy.
Randy D GascoyneDepartment of Pathology & Lymphoid Cancer Research, BC Cancer Agency & BC Cancer Research Centre, Vancouver, BC, Canada.
Lei ZhangCelgene Corporation, Summit, NJ 07901, USA.
Jocelyne FlamentCelgene Corporation, Summit, NJ 07901, USA.
Jacqueline RepiciCelgene Corporation, Summit, NJ 07901, USA.
Umberto VitoloDivision of Hematology, Città della Salute e della Scienza Hospital & University, Torino, Italy.
Mayo Clinic · USBC Cancer Agency · CANational Cancer Institute · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), the major constituent of nongerminal center B-cell-like (non-GCB) DLBCL, is associated with poorer survival outcomes than GCB-type DLBCL. In Phase II studies, lenalidomide combined with R-CHOP (R(2)-CHOP) improved outcomes relative to historical R-CHOP in newly diagnosed DLBCL, particularly in non-GCB cases. ROBUST (CC-5013-DLC-002) is a randomized, double-blind, global, Phase III study of oral lenalidomide (15 mg, days 1-14) plus R-CHOP21 × 6 versus placebo-R-CHOP21 × 6 in patients with previously untreated ABC-type DLBCL. Subtyping is done within 3 calendar days by central laboratory gene-expression profiling of formalin-fixed paraffin-embedded biopsy tissue. The primary end point is progression-free survival. Secondary end points include response rates, overall survival and health-related quality of life.

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDouble-Blind MethodDoxorubicinFemaleHumansLenalidomideLymphoma, Large B-Cell, DiffuseMalePrednisoneResearch DesignRituximabThalidomideVincristineAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinLenalidomidePrednisoneR-CHOP protocolRituximabThalidomideVincristinechemotherapyhematologic/lymphomamolecular oncology

Identifiers

PMID27089170
PMCPMC5551933
OpenAlexW2339030197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.